What are some pro‑kinetic agents for functional dyspepsia?

Prokinetic Agents for Functional Dyspepsia

The prokinetic agents available for functional dyspepsia include acotiamide, itopride, mosapride, tegaserod, metoclopramide, domperidone, cisapride, cinitapride, levosulpiride, and prucalopride, though availability varies significantly by geographic region. 1

First-Line Prokinetics with Evidence Support

According to the 2022 British Society of Gastroenterology guidelines, prokinetics are considered first-line treatment for FD, though their efficacy varies considerably by drug class 1:

Strongest Evidence (Moderate Quality):

• Tegaserod - Strong recommendation with moderate quality evidence 1

Lower Evidence (Low Quality):

• Acotiamide - Weak recommendation, low quality evidence 1
• Itopride - Weak recommendation, low quality evidence 1
• Mosapride - Weak recommendation, low quality evidence 1

Additional Agents from Recent Meta-Analyses:

• Metoclopramide - Showed highest efficacy in network meta-analysis, superior to mosapride, domperidone, itopride, and acotiamide 2
• Cinitapride - Demonstrated better efficacy than mosapride and placebo, with lower risk of adverse events compared to domperidone 2
• Domperidone - Commonly used comparator, though less effective than metoclopramide and cinitapride 2

Critical Geographic Availability Issue

A major caveat: many of these prokinetics are unavailable outside of Asia and the USA 1. This severely limits practical prescribing options in many regions, particularly in Europe where domperidone and metoclopramide may be the only readily available options.

Second-Line Agents with Prokinetic Properties

When first-line prokinetics fail, antipsychotics with prokinetic effects can be considered 1:

• Levosulpiride 25 mg three times daily - Has predominant prokinetic effect, particularly useful for postprandial distress syndrome 3
• Sulpiride 100 mg four times daily 1

Emerging and Investigational Agents

Future research directions include 1:

• 5-HT4 agonists: Prucalopride, velusetrag
• Ghrelin agonists: Relamorelin
• Neurokinin-1 receptor antagonists: Aprepitant, tradipitant

Safety Considerations

Cisapride showed significantly more adverse events than placebo (RR 1.31) and should be avoided 4. Most other prokinetics are well-tolerated with adverse event profiles similar to placebo 1. Common side effects include diarrhea, abdominal discomfort, and nausea 4.

Metoclopramide carries risk of extrapyramidal side effects and should be used cautiously, particularly with long-term therapy 5.

Clinical Application Algorithm

For postprandial distress syndrome (early satiety, postprandial fullness):

• First choice: Tegaserod (if available), cinitapride, or metoclopramide
• Alternative: Levosulpiride 25 mg three times daily
• If unavailable: Acotiamide, itopride, or mosapride

For epigastric pain syndrome:

• Prokinetics are less effective; consider tricyclic antidepressants instead 1, 5

Important limitation: The quality of evidence for prokinetics is predominantly very low to low, with only tegaserod having moderate quality evidence 1. This reflects significant heterogeneity in study designs and outcomes, as well as possible publication bias 4.